Compare Johnson & Johnson (JNJ) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs TeraWulf Inc — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while TeraWulf Inc trades at $13.77 (market cap $6.81B). The key difference: Johnson & Johnson is far larger — about 90.8× TeraWulf Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while TeraWulf Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and TeraWulf Inc for 17 Days on average.
| JNJ | WULF | |
|---|---|---|
Market Cap | $618.09B | $6.81B |
Volume | 6,050,983 | 45,841,998 |
Sector | Health | Financials |
52-Week High | $278.43 | $28.98 |
52-Week Low | $186.00 | $10.99 |
Typical Hold Time | 129 Days | 17 Days |
Enterprise Value | $646.37B | $9.43B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
WULF trades at $13.65, down 5.21% today, amid a bearish technical signal and volatile AI infrastructure sector sentiment. The company reported a net loss of $661.42 million in 2025 with a negative net income margin of -392.64%, while revenue was $168.46 million. Recent news highlights its pivot to AI data centers, with stock movements influenced by sector-wide trends and analyst coverage.
Outlook remains speculative with high valuation ratios (P/S 35.73, P/B 46.24) and persistent losses posing risks, but 100% analyst buy ratings and a $34.92 consensus price target suggest long-term growth potential from AI hosting contracts. Key risks include execution challenges and competitive pressures in the evolving AI infrastructure space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
